Patients

For Patients - Motolimod

Motolimod (formerly VTX-2337)

Motolimod is an investigational drug that is designed to wake up a patient's own immune system to fight cancer. Preclinical studies demonstrate that motolimod enhances various anticancer agents including chemotherapeutics and monoclonal antibody therapies to generate a strong anti-tumor response.

Motolimod activates multiple components of the patient's immune system, resulting in both the recruitment of inflammatory cell populations to the tumor and the induction of an immediate and long-term response.

What Is Cancer Immunotherapy?

Scientists have long believed that the immune system is capable of destroying cancer cells. Recently, researchers have identified ways to assist the immune system to maximize its full ability to recognize and attack cancer cells and tumors. This form of treatment, called immunotherapy, is at the leading edge of cancer research. In recent years, two different types of immunotherapy have been approved by the US Food and Drug and Administration (FDA) for treating cancer. The key to an immunotherapy approach is to enhance the body's immune system to improve its natural ability to identify and destroy cancer cells that have avoided detection. In addition, because the immune system has a memory, immunotherapy may continue to provide protection from relapses even after treatment has stopped.

Ovarian Cancer

To learn more about the clinical trial of motolimod in platinum-resistant ovarian cancer click here or contact us at clinicaltrials@ventirx.com.

Learn More

Head and Neck Cancer

Now Enrolling

To learn more about the clinical trial of motolimod in locally advanced or recurrent head and neck cancer click here or contact us at clinicaltrials@ventirx.com.

Learn More